Rchr
J-GLOBAL ID:200901052274620852
Update date: Sep. 29, 2022
Mizuguchi Junichiro
ミズグチ ジュンイチロウ | Mizuguchi Junichiro
Affiliation and department:
Tokyo Medical University Faculty of Medicine Course of Medicine
About Tokyo Medical University Faculty of Medicine Course of Medicine
Search "Tokyo Medical University Faculty of Medicine Course of Medicine"
Detailed information
Research field (1):
Immunology
Research keywords (2):
免疫学
, Immunology
Research theme for competitive and other funds (4):
アレルギー発症機序に関する研究
リンパ球活性化機構の分子論的解析
Study on the pathogenesis of allergy
Molecular mechanism on the lymphocyte activation
MISC (105):
XZ Jiang, H Toyota, E Takada, T Yoshimoto, T Kitamura, J Yamada, J Mizuguchi. Modulation of mThy28 nuclear protein expression during thymocyte development. TISSUE & CELL. 2003. 35. 6. 471-478
XZ Jiang, H Toyota, E Takada, T Yoshimoto, T Kitamura, J Yamada, J Mizuguchi. Modulation of mThy28 nuclear protein expression during thymocyte development. TISSUE & CELL. 2003. 35. 6. 471-478
T Hirano, Yonekubo, I, K Shimo, J Mizuguchi. CD27 synergizes with CD40 to induce IgM, IgG, and IgA antibody responses of peripheral blood B cells in the presence of IL-2 and IL-10. IMMUNOLOGY LETTERS. 2003. 89. 2-3. 251-257
T Hirano, Yonekubo, I, K Shimo, J Mizuguchi. CD27 synergizes with CD40 to induce IgM, IgG, and IgA antibody responses of peripheral blood B cells in the presence of IL-2 and IL-10. IMMUNOLOGY LETTERS. 2003. 89. 2-3. 251-257
T Hotta, H Suzuki, S Nagai, K Yamamoto, A Imakiire, E Takada, M Itoh, J Mizuguchi. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. JOURNAL OF ORTHOPAEDIC RESEARCH. 2003. 21. 5. 949-957
more...
Professional career (1):
(BLANK)
Committee career (1):
1989 - 日本免疫学会 運営委員
Association Membership(s) (4):
日本臨床免疫学会
, 日本アレルギー学会
, 日本薬学会
, 日本免疫学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in
researchmap
.
For details, see here
.
Return to Previous Page
TOP
BOTTOM